{Reference Type}: Journal Article
{Title}: Dry eye disease adverse reaction of pharmacological treatment for early-stage breast cancer.
{Author}: He J;Zhou Y;Xiu M;Liu Y;Ma B;Duan H;Chen J;Zhao L;Lan Q;Ma Y;Wang X;Qi H;
{Journal}: Ocul Surf
{Volume}: 34
{Issue}: 0
{Year}: 2024 Jul 20
{Factor}: 6.268
{DOI}: 10.1016/j.jtos.2024.07.005
{Abstract}: Breast cancer is the most prevalent cancer worldwide. With advancements in breast cancer diagnosis and treatment, the prognosis of patients with early-stage cancer has significantly improved. Enhancing the long-term quality of life of patients after antineoplastic therapy, including visual quality, has become a crucial research focus. This review aims to comprehensively summarize dry eye disease adverse reaction resulting from pharmacotherapy for early-stage breast cancer. Through a review of the relevant literature, this study explored the etiology, clinical features, and potential therapeutic strategies for drug-induced dry eye disease in breast cancer treatment. A thorough understanding of the medication-induced dry eye disease adverse reaction aid clinicians in monitoring and managing patients' ocular health more effectively, facilitating early diagnosis and intervention, preventing complications, and ensuring optimal visual protection for patients undergoing breast cancer treatment.